The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, C.-C.
Right arrow Articles by Ferrone, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, C.-C.
Right arrow Articles by Ferrone, S.
The Journal of Immunology, 2005, 174: 1462-1471.
Copyright © 2005 by The American Association of Immunologists

Immune Selection of Hot-Spot {beta}2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1

Chien-Chung Chang*, Michael Campoli*, Nicholas P. Restifo{dagger}, Xinhui Wang* and Soldano Ferrone2,*

* Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263; and {dagger} National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

Scanty information is available about the mechanisms underlying HLA class I Ag abnormalities in malignant cells exposed to strong T cell-mediated selective pressure. In this study, we have characterized the molecular defects underlying HLA class I Ag loss in five melanoma cell lines derived from recurrent metastases following initial clinical responses to T cell-based immunotherapy. Point mutations in the translation initiation codon (ATG->ATA) and in codon 31 (TCA->TGA) of the {beta}2-microglobulin ({beta}2m) gene were identified in the melanoma cell lines 1074MEL and 1174MEL, respectively. A hot-spot CT dinucleotide deletion within codon 13–15 was found in the melanoma cell lines 1106MEL, 1180MEL, and 1259MEL. Reconstitution of {beta}2m expression restored HLA class I Ag expression in the five melanoma cell lines; however, the HLA-A and HLA-B,-C gene products were differentially expressed by 1074MEL, 1106MEL, and 1259MEL cells. In addition, in 1259MEL cells, the Ag-processing machinery components calnexin, calreticulin, and low m.w. polypeptide 10 are down-regulated, and HLA-A2 Ags are selectively lost because of a single cytosine deletion in the HLA-A2 gene exon 4. Our results in conjunction with those in the literature suggest the emergence of a preferential {beta}2m gene mutation in melanoma cells following strong T cell-mediated immune selection. Furthermore, the presence of multiple HLA class I Ag defects within a tumor cell population may reflect the accumulation of multiple escape mechanisms developed by melanoma cells to avoid distinct sequential T cell-mediated selective events.




This article has been cited by other articles:


Home page
JCOHome page
J. M. Kirkwood, A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. Butterfield, and H. J. Gogas
Next Generation of Immunotherapy for Melanoma
J. Clin. Oncol., July 10, 2008; 26(20): 3445 - 3455.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-C. Chang, T. Ogino, D. W. Mullins, J. L. Oliver, G. V. Yamshchikov, N. Bandoh, C. L. Slingluff Jr., and S. Ferrone
Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel beta2-Microglobulin Loss-of-function in Melanoma Cells
J. Biol. Chem., July 7, 2006; 281(27): 18763 - 18773.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. W. Chen, T. Uno, and B. R. Ksander
Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection
J. Immunol., July 1, 2006; 177(1): 162 - 168.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al.
Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity.
Cancer Res., June 15, 2006; 66(12): 6387 - 6394.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Purbhoo, D. H. Sutton, J. E. Brewer, R. E. Mullings, M. E. Hill, T. M. Mahon, J. Karbach, E. Jager, B. J. Cameron, N. Lissin, et al.
Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors.
J. Immunol., June 15, 2006; 176(12): 7308 - 7316.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Paschen, N. Arens, A. Sucker, K. M. Greulich-Bode, E. Fonsatti, A. Gloghini, S. Striegel, N. Schwinn, A. Carbone, R. Hildenbrand, et al.
The Coincidence of Chromosome 15 Aberrations and {beta}2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma.
Clin. Cancer Res., June 1, 2006; 12(11): 3297 - 3305.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Liu, S. A. Caldwell, K. M. Greeneltch, D. Yang, and S. I. Abrams
CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape
J. Immunol., March 15, 2006; 176(6): 3374 - 3382.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.